DE-QPS-HOLDINGS
26.6.2024 21:00:28 CEST | Business Wire | Press release
QPS, a leading global contract research organization (CRO), is pleased to announce new laboratory services capabilities. The central laboratory, leukopak cell therapy facility, and enhanced PBMC capabilities will complement existing bioanalysis, translational medicine and peripheral blood mononuclear cell (PMBC) laboratories and extend the current QPS full-service global CRO offerings.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240626261072/en/
QPS Missouri, a division of QPS Holdings, LLC, a global Contract Research Organization. QPS Missouri conducts Phase I-IV clinical trials and houses central lab, safety lab, PBMC and cell production services in Springfield, Missouri. (Photo: Business Wire)
QPS now offers clinical trial sample analysis services and leukopak cell therapy products from its newly expanded clinical trials unit conveniently located in Springfield, Missouri. In addition, QPS has also expanded PBMC service offerings from its Miami, Florida location into its Springfield, Missouri laboratories. The new facilities are housed with an existing clinical (safety) laboratory, a modern self-contained pharmacy, and dedicated space to build and ship clinical trial kits.
The modern central laboratory for sample analysis complements the existing on-site safety laboratory, equipped with the most up-to-date technologies for chemistry, urinalysis, serology, coagulation, and hematology testing. These capabilities, designed to monitor subject safety during ongoing clinical trials, will remain as core services for QPS in-house clinical trials.
The new leukopak products collection and processing facility is designed to meet the exponential growing demand for blood products to support cell therapy research and QPS is ideally placed to provide this service. QPS Missouri has a database of over 35,000 potential study participants, who can be contacted as potential blood donors for leukopak products.
“There is significant unmet demand in this rapidly growing area of cell therapy products, which represents a tremendous opportunity for QPS. Over 3,000 cell and gene therapy programs are currently in progress representing a 20% increase over the past five years. These programs require leukopak products to move forward, and as a result this market is forecasted to grow by a CAGR of more than 8% over the next six years,” said Benjamin Chien, Chairman, President and CEO of QPS.
The enhanced PBMC services include a new PBMC processing lab at the Springfield location, complementing the existing lab at QPS Miami in Miami, Florida. This new lab will support a current unmet need for PBMC processing in the midwestern USA. PBMC sample analysis is a time-consuming process, typically required in vaccine trials, and it is best done in a lab adjacent to the clinical trial unit. QPS is uniquely positioned to offer this service.
“These new facilities, services and products extend our full service CRO capabilities, putting QPS in a position to offer clients comprehensive clinical research services in one location. The central lab, PBMC lab, and the leukopack facility complement and enhance our current 240 bed clinical trials unit, safety laboratory, modern self-contained pharmacy, and clinical trial kit production facility,” said Brendon Bourg, Vice President, Early Phase Clinical and Head of Administration at QPS Missouri.
ABOUT QPS HOLDINGS, LLC
QPS is a global, full-service, GLP/GCP-compliant contract research organization (CRO) delivering the highest grade of discovery, bioanalysis, preclinical and clinical drug development services. Since 1995, QPS has grown from a small bioanalysis shop into a full-service CRO with 1,100+ employees in the US, Europe, and Asia. Today, QPS offers expanded pharmaceutical contract R&D services with special expertise in pharmacology, DMPK, toxicology, bioanalysis, translational medicine, clinical trials, and clinical research services. An award-winning leader focused on bioanalysis and clinical trials, QPS is known for proven quality standards, technical expertise, a flexible approach to research, client satisfaction, and turnkey laboratories and facilities. Through continual enhancements in capacities and resources, QPS stands tall in its commitment to delivering superior quality, skilled performance and trusted service to its valued customers. For more information, visit www.qps.com or email info@qps.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240626261072/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Reply Announces a Partnership With Mistral AI to Develop Sovereign and Enterprise-grade Artificial Intelligence Solutions18.3.2026 09:00:00 CET | Press release
Reply [EXM, STAR: REY] today announced a new partnership agreementwithAI leader Mistral AI aimed at accelerating the adoption of local, customisable, secure and enterprise-grade generative AI solutions at scale. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260318232777/en/ Through this collaboration, Reply and Mistral AI provide a trusted and secure environment on European infrastructures, accelerating the adoption of advanced AI solutions while enabling organizations with stringent regulatory, privacy and data protection requirements to fully leverage generative AI. At the core of the collaboration is a shared vision of frontier AI, designed to enable organizations to adopt AI solutions while ensuring data control, protection of sensitive information, compliance with regulatory requirements and deployment on European infrastructures. By combining Mistral AI’s high-performance AI models with Reply’s expertise in designing
Samsung Bioepis Enters into Partnership Agreement with Sandoz for Up to Five Next-Generation Biosimilar Candidates18.3.2026 08:30:00 CET | Press release
The agreement covers up to five assets, including SB36, a biosimilar candidate referencing Entyvio (vedolizumab), for collaboration of development and commercialization in global markets excluding China, Hong Kong, Taiwan, Macau, and Republic of KoreaSamsung Bioepis continues to pave the way for access to life-changing medicines by advancing a biosimilar pipeline across immunology and oncology Samsung Bioepis Co., Ltd. announced today that the company has entered into a global license, development and commercialization agreement (DCA) with Sandoz for up to five biosimilar candidates under development by Samsung Bioepis, including SB36, a biosimilar candidate referencing Entyvio1 (vedolizumab). The other terms of the agreement remain confidential. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260318826412/en/ Samsung Bioepis office in Songdo, Incheon, Republic of Korea Under the terms of the agreement, Samsung Bioepis will b
Epassi Appoints Three Senior Leaders to Accelerate European Growth18.3.2026 08:00:00 CET | Press release
Epassi Group, a leading European multi-benefits technology platform, today announced the appointments of Phil Jones as Chief Revenue Officer (CRO), Ross Seychell as Chief People Officer (CPeO), and Cho Hwang as Chief Technology Officer (CTO), strengthening its leadership team as the company enters its next phase of expansion. Cho Hwang joined Epassi on December 1, 2025. He brings extensive global technology leadership experience from companies including HelloFresh, Coupang, and Nordstrom. At Epassi, Cho leads the company’s technology strategy and engineering organisation as the platform continues to scale across Europe. His experience will support Epassi’s ambition to further expand its multi-benefits ecosystem for employers, employees, and partners. Phil Jones joined Epassi on March 2. He brings extensive experience across HR technology and the full Human Capital Management lifecycle, having held senior leadership roles across Sales, Revenue Operations, and Customer Success at global
AiDEN Are Collaborating With Volvo Group Through the Innovation Hub CampX in a Proof-of-Value Project Solving Real Customer Needs18.3.2026 05:00:00 CET | Press release
In December 2024, a new regulatory requirement was introduced in Poland related to SENT (System for Electronic Transport Supervision) for tracking high-risk goods transported within the country. In regard to this, a project to validate one of AiDEN's services/products within the platform was initiated. This was done in a project with Volvo Trucks through CampX, Volvo Group’s global innovation arena for technology and business transformation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260317838896/en/ AiDEN’s SENT GEO compliance service displayed within a Volvo truck’s in-vehicle infotainment system, enabling automated geolocation reporting for Poland’s System for Electronic Transport Supervision (SENT). Developed through a collaboration between AiDEN Automotive and Volvo Group’s CampX innovation hub, the integrated solution allows fleets to meet SENT requirements without external GPS hardware or aftermarket installations
LTM Named NVIDIA Partner Network ‘Rising Star Consulting Partner of the Year’ at NVIDIA GTC 202618.3.2026 03:30:00 CET | Press release
LTM, the Business Creativity partner to the world’s largest enterprises, has been recognized as the NVIDIA Partner Network (NPN) ‘Rising Star Consulting Partner of the Year’ at NVIDIA GTC 2026. The award recognizes LTM’s strong collaboration with NVIDIA and its growing impact in helping enterprises move from AI experimentation to scalable, enterprise-ready adoption. The NVIDIA Partner Network (NPN) brings together a global ecosystem of technology and consulting partners working closely with NVIDIA to deliver advanced AI solutions. Being an NPN partner is about collaborating deeply with NVIDIA to help clients transition from AI pilots to enterprise-scale deployments combining NVIDIA’s advanced AI technologies with LTM’s industry and domain expertise to drive real-world outcomes. The Rising Star Consulting Partner of the Year award highlights LTM’s momentum in delivering AI solutions that are production-grade, secure, and designed for enterprise scale. This NPN award is a significant rec
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
